There are currently 66 clinical trials in Arlington, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Texas Clinical Research Institute, GSK Investigational Site, Texas Clinical Research Institute, Llc and Texas Retina Associates. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
NCT05705440
Recruiting
The purpose of this follow-up study is to describe the safety in subsequent pregnancies in participants who were previously administered the RSVPreF3 maternal vaccine or control during any prior RSV MAT study. The study participants enrolled in this follow-up study received RSVPreF3 maternal vaccination (any dose) or controls during the following prior RSV MAT studies: RSV MAT-001 (NCT03674177), RSV MAT-004 (NCT04126213), RSV MAT-010 (NCT05045144), RSV MAT-011 (NCT04138056), RSV MAT-009 (NCT046... Read More
Gender:
Female
Ages:
Between 9 years and 49 years
Trial Updated:
08/30/2023
Locations: GSK Investigational Site, Arlington, Texas
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636
Recruiting
RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for treatment of wet AMD, b... Read More
Gender:
All
Ages:
Between 50 years and 89 years
Trial Updated:
08/17/2023
Locations: Texas Retina Associates, Arlington, Texas
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Register for Updates
A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
NCT05577715
Recruiting
The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/17/2023
Locations: Texas Oncology - Arlington North, Arlington, Texas
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (AMD) or Subjects With Diabetic Macular Edema (DME)
NCT05387837
Recruiting
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME)
Gender:
All
Ages:
18 years and above
Trial Updated:
02/09/2023
Locations: Texas Retina Associates - Arlington, Arlington, Texas
Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Register for Updates
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
NCT04880187
Recruiting
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Texas Clinical Research Institute, Arlington, Texas
Conditions: Non Alcoholic Steatohepatitis (NASH)
Register for Updates
Creating Physical Objects With 3D Printers to Stimulate Reminiscing for Memory Loss [2 R44 AG049548-02A1]
NCT03625973
Recruiting
In 2013 an estimated 5 million people age 65 and older had Alzheimer's disease. Longer life spans and aging baby boomers will cause this number to grow rapidly. More than 50% of residents in assisted living and nursing homes have some form of dementia or cognitive impairment and the number is increasing every day. As a form of person-centered, non-pharmacological dementia care, Reminiscence Therapy (RT) holds considerable promise. Improvements in mood, quality of life, social interaction, cogni... Read More
Gender:
All
Ages:
All
Trial Updated:
04/18/2022
Locations: University of Texas Arlington, Arlington, Texas
Conditions: Dementia
Register for Updates